Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - Scorecard - MDSpire
Advertisement
Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system
Clinical Scorecard: Interstitial Lung Disease Linked to Anticancer Drugs in Breast, Ovarian, and Prostate Cancers: A Study Utilizing the FDA Adverse Event Reporting System
At a Glance
Category
Detail
Condition
Key Mechanisms
Direct alveolar epithelial injury or immune-mediated mechanisms leading to pulmonary fibrosis.
Target Population
Care Setting
Key Highlights
Trastuzumab deruxtecan (T-DXd) showed the highest ILD reporting association.
Older age and lower body weight are associated with increased ILD reporting.
Drug-induced ILD has an overall mortality rate of approximately 18.3% among severe cases.
Guideline-Based Recommendations
Diagnosis
Monitor respiratory symptoms and oxygenation during treatment.
Management
Consider early ILD monitoring in patients receiving anticancer agents.
Monitoring & Follow-up
Assess for exertional dyspnea, dry cough, and reduced exercise tolerance.
Risks
High risk of death associated with severe ILD related to anticancer agents.
Patient & Prescribing Data
Patients with sex hormone-sensitive solid tumors.
Multiple classes of anticancer agents are associated with ILD, including mTOR inhibitors, PD-1/PD-L1 inhibitors, and antibody-drug conjugates.
Clinical Best Practices
Conduct a structured review of patient factors such as age and body weight.
Utilize disproportionality analysis for ILD reporting associations.
